Ayad Bahadorimonfared
1, Amirhesam Alirezaei
2*, Elham Zare
3, Mahmood Bakhtiyari
4,51 Department of Health & Community Medicine, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Clinical Research and Development Center at Shahid Modarres Hospital , Department of Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Department of Internal Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Department of Community Medicine, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
5 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Abstract
Acute kidney injury (AKI) is defined as an abrupt or rapid decline in renal filtration function. Erythropoietin (EPO) as a hematopoietic and multifunctional hormone is produced primarily by kidney. Many investigations have shown that EPO as an antioxidant agent has shown several effects such as anti-apoptotic, antioxidant, and anti-inflammatory and also angiogenic activities. The biological activities of EPO are mediated by binding to its receptor (EPOR). The potential role of EPO in kidney is related to the presence of functional EPOR in renal mesangial cells, tubular epithelial cells and the glomerulus. Antioxidants and reactive oxygen species (ROS) scavengers such as EPO, can protect the kidneys against conditions that induce nephrotoxicity. Most studies in the field of renoprotective effects of EPO have focused on AKI models. In this paper we sought to review the ameliorative effects of EPO against various agents or conditions that induce nephrotoxicity including ischemia/reperfusion injury (IRI), cisplatin, gentamicin, rhabdomyolysis, amikacin and vancomycin.
Implication for health policy/practice/research/medical education:
This review paper showed that erythropoietin (EPO) is suitable as a nephroprotective agent. The nephroprotective efficacy of EPO is associated with its direct and indirect antioxidant properties. The activities of EPO are mediated by binding to EPO-receptor and the positive role of EPO in the kidney is related to presence of functional EPO-receptor in renal mesangial cells and renal tubular epithelial cells. These findings revealed an association between administration of EPO and reduction of renal injuries, induced by cisplatin, gentamicin, rhabdomyolysis, vancomycin and amikacin in rats and renal ischemia/reperfusion injury (IRI) as one of the most common causes of acute kidney injury. Previous studies and this review showed the encouraging results on potential therapeutic impact of EPO in acute kidney injury.
Please cite this paper as: Bahadorimonfared A, Alirezaei A, Zare E, Bakhtiyari M. Beyond hematopoietic property; administration of erythropoietin for nephroprotection. J Renal Inj Prev. 2017;6(4):292-296. DOI: 10.15171/jrip.2017.55.